Fidelity Select Pharmaceuticals FPHAX NASDAQ · Financials · United States
$39.13 +0.00% +$0.00
Summary
Fidelity Select Pharmaceuticals is a mutual fund. It does not trade on an exchange: you buy it from the fund company at a price set once a day. Positions inside: 48. The ten largest make up 73% of the fund.
- Positions
- 48
- Dividend yield
- 4.28%
What speaks for it
- Average yearly growth over the last ten years: 7.9%.
What to watch
- The ten largest positions make up 73% of the fund, so its result rests on a few names.
- In the last five years its price once dropped by 30% from its high.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- +15%
- 3 months
- +13%
- This year
- +25%
- 1 year
- +26%
- 3 years
- +71%
- 5 years
- +50%
- 10 years
- +114%
- Avg. market cap
- $428.6B
- P/E
- 31.3x
- Forward P/E
- 18.6x
- P/S
- 4.6x
- P/B
- 4.9x
- P/FCF
- 20.4x
- EV/EBITDA
- 19.9x
- Dividend yield
- 1.11%
- ROIC
- 10.8%
- ROE
- 23.8%
- Gross margin
- 72.5%
- Operating margin
- -1.2%
- Net margin
- -10.1%
- Payout ratio
- 34.9%
- Net debt/EBITDA
- 2.8x
- Beta
- 0.65
Weighted average of the 35 largest companies, which make up 92% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Concentrated- 1 LLEli Lilly LLY 25%
- 2 GSGSK GSK 8.1%
- 3 VTViatris VTRS 5.9%
- 4 MRMerck & Co. MRK 5.9%
- 5 Astrazeneca PLC (United States) 4.9%
- 6 BMBristol-Myers Squibb BMY 4.8%
- 7 GIGilead Sciences GILD 4.6%
- 8 MRModerna MRNA 4.6%
- 9 UCUCB UCB.BR 4.5%
- 10 RORoche Holding AG ROP.SW 4.4%
Positions in the fund: 48. The ten largest make up 73% of it.
Composition as of Nov 7, 2026.
Where is it spread?
By company size
- Mega cap 44%
- Large cap 44%
- Mid cap 9.1%
- Small cap 3.4%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M. Counted from the companies that make up 92% of the fund.
Largest size group: Mega cap (44%).
What does it cost me?
We do not know the costs of this fund.
How has it done?
Growing over the long run- A year on average, 10 years
- +7.9%
- Deepest drop
- -30%
- Yearly volatility
- 22%
Average yearly growth over the last ten years: 7.9%. Deepest drop in these years: 30% below the earlier high.
Does it pay dividends?
Yes, it pays out- Yield
- 4.28%
- Payments a year
- 2
- Last payment
- $0.78
Over the last 12 months it paid $1.68 per share, which is 4.28% of today's price. The last payment was $0.78 on Apr 10, 2026.
How expensive are the companies inside?
Rather expensive- P/E of the companies inside
- 31.3
- Average Bulios Score
- 55 out of 100
Weight by Bulios Fair Price
- Undervalued 30%
- Fairly valued 19%
- Overvalued 51%
On average the companies inside trade for 31.3 times their yearly profit. By Fair Price, 51% of the rated weight comes out as overvalued.
Counted from its largest companies (35), which make up 92% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Can I buy it as an ETF?
A mutual fund is bought from the fund company. These ETFs hold much of the same and trade on an exchange, so an ordinary broker carries them.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
IH IHE iShares U.S. Pharmaceuticals ETF | United States | 0.37% | $1.21B | +37% | Pays out | 50% |
PP PPH VanEck Pharmaceutical ETF | United States | 0.36% | $1.07B | +22% | Pays out | 41% |
HE HEMI Hartford Equity Premium Income ETF | United States | 0.58% | $35.7M | - | Pays out | 36% |
ME MEDX Horizon Kinetics Medical ETF | United States | 0.85% | $17.7M | +16% | Pays out | 33% |
FT FTXH First Trust Nasdaq Pharmaceuticals ETF | United States | 0.60% | $1.18B | +40% | Pays out | 31% |
IY IYH iShares U.S. Healthcare ETF | United States | 0.37% | $4.72B | +22% | Pays out | 29% |